AGN phase 1 DMT studyAGN is advancing phase 1 DMT clinical stroke study and the first subject has been dosed. Will be helpful in planning for phase 2 as well. AGN.c is the first company in the world to investigate DMT for stroke. Phase 1 will test 60 healthy patients and focus on the safety and tolerability of DMT. There are very few treatment options for the treatment of stroke so its great to see AGN move forward with this study. Data should be out in Q3 then phase 2 studies in stroke patients will begin at the end of year.
https://www.youtube.com/watch?v=BfjAjt1jxuU&t=1s